NKAPL and cancer: For example, patients with higher expression levels of NKAPL have better OS prognoses than those with lower expression levels of NKAPL in four cancer types (ACC, KIRP, LGG, and PAAD), and better DFS prognoses in three cancer types (ACC, KIRP, and THYM) (Figure 5A, log-rank test, unadjusted P-value < 0.05).